Celgene Corp (NASDAQ:CELG)

Biotech will move up over the coming years.

There are currently 150 shares in my "fund" with break-even of around 58.02 USD.
http://caps.fool.com/Blogs/fund-trades/687712.
http://twitter.com/portefeuillefun.

#16 Intrinsic value, Stockscouter 9

I've had this stock on my watch list for quite some time now. But after listening to Cramer's compelling argument for positive forward earnings tonight , and checking the numbers, I am sold on this stock as a winner in my portfolio.

Celgene is the only major corp. in its sector which is showing bullish trends in almost every aspect of its business. With longer lives, diseases such as cancer will become even more prominent. Thus demand of medical proffessionals and tools will rise.

Revlimid is just one example of their science & technology. Comapred to other pharma companies, CELG has their act together in a way that does not easily show up on a balance sheet.

This company should profit from its cancer drugs for the forseeable future.

Relative Strength Index of 90 gives confidence of continued increased value in short term

ibd sector leader . aug 2011 it bought back 2 billion $ in its own stock. owns rights to ritalin drug.

Looking for a safe place with growth potential over the summer...this might be it.

key03, no dividend, neutral

Great Margins and Revenue growth - price performance this year doesn't seem to reflect. Identified in my YCharts/FinViz double screen.

Perfect

Looking for S&P 500 stocks with a reasonable valuation. I have a 99 target price.

Big investment in discovery and production of new therapies. Monitizing these treatments will take time, but could be huge.

S&P 5 star stock ; S&P500 2010 low on 6/29/2010

Sales growth and earning growth will continue to be in excess of 20% per annum for the next 2-4 years

Top biotech company that could break out of its 9 month window (50-60) in the next few months.

health reform good for biotechs